Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

Balb/c FasKO mice develop allergic blepharitis associated with hyper-production of IgE

Authors: Ayumi Fukuoka, Shizue Yumikura-Futatsugi, Suzuka Takahashi, Hirotaka Kazama, Kenji Nakanishi, Shin Yonehara

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Fas is a member of the TNF receptor family and crucial for induction of apoptosis. MRL- lpr/lpr mice, which carry a mutation of Fas, spontaneously develop systemic autoimmune disease including arthropathy, indicating that Fas plays an important role in elimination of self-reactive immunocytes by apoptosis. In addition to autoimmune diseases, we found a novel phenotype of FasKO mice exclusively in Balb/c genetic background that is allergic blepharitis. Allergic blepharitis is revealed in Balb/c FasKO mice from 15 week-old and about 85% of the mice suffered from allergic blepharitis at 35 week-old. Serum concentrations of both IgG1 and IgE Abs were about 100-times higher in 20-week old FasKO mice than in WT mice; however, there was no significant difference between WT and FasKO mice in the ability of B cells to produce IgG1 and IgE Abs in the presence of IL-4 and anti-CD40 Ab inducing co-stimulatory signals. Additionally, the production of IL-4 by T cells was same. These results suggested that other type of cells enhanced IgG1 and IgE Abs production from B cells in Balb/c FasKO mice. To identify the cells enhancing IgG1 and IgE Abs production, we cultured B cells in vitro in the presence of IL-4 and anti-CD40 Ab together with various types of cells from Balb/c FasKO mice. In the result, we found FasKO non-T non-B cells upregulated the production of both IgG1 and IgE from B cells. Moreover, the number of these cells was specifically increased in Balb/c FasKO mice.All the results indicate that these cells enhance production of IgG1 and IgE from B cells in the presence of IL-4 and anti-CD40 Ab, and excessive accumulation of these cells may cause allergy via hyper-production of IgE.
Literature
1.
go back to reference Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fujii H, Koyasu S: Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010, 463: 540-544. 10.1038/nature08636.CrossRefPubMed Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fujii H, Koyasu S: Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010, 463: 540-544. 10.1038/nature08636.CrossRefPubMed
2.
go back to reference Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010, 464: 1367-1370. 10.1038/nature08900.PubMedCentralCrossRefPubMed Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010, 464: 1367-1370. 10.1038/nature08900.PubMedCentralCrossRefPubMed
Metadata
Title
Balb/c FasKO mice develop allergic blepharitis associated with hyper-production of IgE
Authors
Ayumi Fukuoka
Shizue Yumikura-Futatsugi
Suzuka Takahashi
Hirotaka Kazama
Kenji Nakanishi
Shin Yonehara
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3620

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.